Compare · FLXN vs MYOK
FLXN vs MYOK
Side-by-side comparison of Flexion Therapeutics, Inc. (FLXN) and MyoKardia, Inc. (MYOK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FLXN and MYOK operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- FLXN carries a market cap of $458.9M.
- FLXN has more recent analyst coverage (7 ratings vs 0 for MYOK).
- Company
- Flexion Therapeutics, Inc.
- MyoKardia, Inc.
- Price
- $25.60+0.16%
- -
- Market cap
- $458.9M
- -
- 1M return
- +2.03%
- -
- 1Y return
- +0.35%
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 7
- 0
Flexion Therapeutics, Inc.
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Latest FLXN
- Avilar Therapeutics Appoints Adam Muzikant, PhD, as Chief Business Officer
- SEC Form 15-12B filed by Flexion Therapeutics, Inc.
- SEC Form EFFECT filed by Flexion Therapeutics, Inc.
- SEC Form 4 filed by Newtyn Management, Llc
- SEC Form 3: New insider Newtyn Management, Llc claimed ownership of 5,900,000 shares
- SEC Form 4: Stejbach Mark returned $107,364 worth of shares to the company (12,631 units at $8.50), closing all direct ownership in the company to cover taxes
- SEC Form 4: Milinazzo Alan returned $233,325 worth of shares to the company (27,450 units at $8.50), closing all direct ownership in the company to satisfy withholding tax
- SEC Form 4: Merrifield C Ann returned $161,500 worth of shares to the company (19,000 units at $8.50), closing all direct ownership in the company to cover withholding tax
- SEC Form 4: Lukatch Heath returned $76,500 worth of shares to the company (9,000 units at $8.50), closing all direct ownership in the company to satisfy tax liability
- SEC Form 4: Kwo Elizabeth returned $38,250 worth of shares to the company (4,500 units at $8.50), closing all direct ownership in the company (tax liability)
Latest MYOK
- FDA Approval for CAMZYOS issued to MYOKARDIA INC
- MyoKardia Presents Mavacamten Clinical and Non-Clinical Data at the American Heart Association’s Scientific Sessions 2020
- MyoKardia Collaborates with the American College of Cardiology and PINNACLE/Veradigm to Launch Patient Registry of Hypertrophic Cardiomyopathy
- MyoKardia Reports Third Quarter 2020 Financial Results
- Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
- MyoKardia Announces Awardees of the Second Annual MyoSeeds™ Research Grants Program
- Bristol Myers Squibb and MyoKardia Announce Expiration of HSR Act Waiting Period
- MyoKardia Announces Multiple Abstracts Selected for Presentation at the Upcoming American Heart Association’s Annual Scientific Sessions 2020
- ALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - MR, MYOK, CBLI, SBPH, PTI, PRCP
- SHAREHOLDER ALERT: WeissLaw LLP Reminds MYOK, PTI, BMCH and GHIV Shareholders About Its Ongoing Investigations